迪安诊断收盘下跌3.46%，最新市净率1.36，总市值89.06亿元

Group 1 - The core viewpoint of the news is that Dian Diagnostics has experienced a significant decline in both revenue and net profit in the first quarter of 2025, indicating potential challenges for the company [1] - As of the first quarter of 2025, Dian Diagnostics reported a revenue of 2.365 billion yuan, a year-on-year decrease of 20.45%, and a net profit loss of approximately 21 million yuan, a year-on-year decline of 190.66% [1] - The company's latest closing stock price was 14.25 yuan, down 3.46%, with a market-to-book ratio of 1.36 and a total market capitalization of 8.906 billion yuan [1] Group 2 - Dian Diagnostics is primarily engaged in providing disease-oriented in vitro diagnostic products and medical testing services to various healthcare institutions, including hospitals and community health service centers [1] - The company has 11 institutional investors holding a total of 55.2263 million shares, with a combined market value of 877 million yuan [1] - The average price-to-earnings (PE) ratio for the industry is significantly higher at 37.94 compared to Dian Diagnostics' PE ratio of -22.18, indicating a potential undervaluation relative to industry peers [2]